Cargando…

The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)

The discovery of asunaprevir (1) began with the concept of engaging the small and well-defined S(1)’ pocket of the hepatitis C virus (HCV) NS3/4A protease that was explored in the context of tripeptide carboxylic acid-based inhibitors. A cyclopropyl-acyl sulfonamide moiety was found to be the optima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meanwell, Nicholas A., Rajamani, Ramkumar, Scola, Paul M., Sun, Li-Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123690/ http://dx.doi.org/10.1007/7355_2018_58

Ejemplares similares

Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
por: Soumana, Djadé I., et al.
Publicado: (2014)

The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
por: Gentile, Ivan, et al.
Publicado: (2014)

Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition
por: Nettles, James H., et al.
Publicado: (2014)

Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
por: Kumada, Hiromitsu, et al.
Publicado: (2014)

Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
por: de Ruiter, Petra E, et al.
Publicado: (2018)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease
por: Wadood, Abdul, et al.
Publicado: (2013)

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
por: Osawa, Mayu, et al.
Publicado: (2018)

The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors
por: Lambert, Sebastian M, et al.
Publicado: (2014)

Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation
por: Lim, Yun-Sook, et al.
Publicado: (2021)

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships
por: Hu, Katherine, et al.
Publicado: (2020)

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking
por: Karpiński, Tomasz M., et al.
Publicado: (2023)

Treatment of HCV NS3/4a Protease Inhibitor Experienced Patients with Sofosbuvir Containing Regimens in an Outpatient Clinic
por: Gilroy, Shelley, et al.
Publicado: (2017)

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
por: Gao, Min, et al.
Publicado: (2010)

Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action
por: Langley, David R, et al.
Publicado: (2015)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease
por: Bharadwaj, Shiv, et al.
Publicado: (2019)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
por: Canini, Laetitia, et al.
Publicado: (2017)

Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
por: Saalau-Bethell, Susanne M., et al.
Publicado: (2012)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients
por: Khan, Hafeez Ullah, et al.
Publicado: (2020)

Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener
por: B, Uma Reddy, et al.
Publicado: (2020)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors
por: Matthew, Ashley N., et al.
Publicado: (2020)

A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach
por: Riaz, Muhammad, et al.
Publicado: (2023)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

Engineered Toxins “Zymoxins” Are Activated by the HCV NS3 Protease by Removal of an Inhibitory Protein Domain
por: Shapira, Assaf, et al.
Publicado: (2011)

Investigation of some benzoquinazoline and quinazoline derivatives as novel inhibitors of HCV-NS3/4A protease: biological, molecular docking and QSAR studies
por: Abuelizz, Hatem A., et al.
Publicado: (2020)

1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease
por: Omar, Abdelsattar M., et al.
Publicado: (2020)

The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region
por: Hamad, Hamzah A., et al.
Publicado: (2016)

Allosteric Inhibitors of Zika Virus NS2B-NS3 Protease Targeting Protease in “Super-Open” Conformation
por: Meewan, Ittipat, et al.
Publicado: (2023)

Phosphonate inhibitors of West Nile virus NS2B/NS3 protease
por: Skoreński, Marcin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_if3p72sc1gilljt0p7tp9ro9s8